Xeris Accounts Payable from 2010 to 2024

XERS Stock  USD 3.42  0.04  1.18%   
Xeris Pharmaceuticals Accounts Payable yearly trend continues to be comparatively stable with very little volatility. Accounts Payable is likely to outpace its year average in 2024. Accounts Payable is the amount Xeris Pharmaceuticals owes to suppliers or vendors for products or services received but not yet paid for. It represents Xeris Pharmaceuticals' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2016-12-31
Previous Quarter
5.8 M
Current Value
7.5 M
Quarterly Volatility
4.1 M
 
Covid
Check Xeris Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xeris Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 5 M, Depreciation And Amortization of 13.8 M or Interest Expense of 27.9 M, as well as many indicators such as Price To Sales Ratio of 1.88, Dividend Yield of 0.0 or Days Sales Outstanding of 154. Xeris financial statements analysis is a perfect complement when working with Xeris Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Xeris Pharmaceuticals Correlation against competitors.
For more information on how to buy Xeris Stock please use our How to Invest in Xeris Pharmaceuticals guide.

Latest Xeris Pharmaceuticals' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Xeris Pharmaceuticals over the last few years. An accounting item on the balance sheet that represents Xeris Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Xeris Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Xeris Pharmaceuticals' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Xeris Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Xeris Accounts Payable Regression Statistics

Arithmetic Mean3,867,017
Geometric Mean2,538,753
Coefficient Of Variation101.49
Mean Deviation3,134,156
Median1,315,000
Standard Deviation3,924,483
Sample Variance15.4T
Range11.3M
R-Value0.80
Mean Square Error5.8T
R-Squared0.65
Significance0.0003
Slope706,149
Total Sum of Squares215.6T

Xeris Accounts Payable History

202412.1 M
202311.6 M
20224.6 M
20218.9 M
20203.1 M
20195.6 M
2018866 K

About Xeris Pharmaceuticals Financial Statements

Xeris Pharmaceuticals shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although Xeris Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Xeris Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Xeris Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Accounts Payable11.6 M12.1 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Xeris Stock Analysis

When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.